Hydroxyurea (Standard)

• Description :

  Hydroxyurea (Standard) is the analytical standard of Hydroxyurea. This product is intended for research and analytical applications. Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase. Hydroxyurea shows anti-orthopoxvirus activity.

• Product Name Alternative :

  Hydroxycarbamide (Standard)

• UNSPSC :

  12352211

• Target :

  Apoptosis; Autophagy; DNA/RNA Synthesis; HIV; Orthopoxvirus; Reference Standards

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Others

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/hydroxyurea-standard.html

• Purity :

  97.96

• Smiles :

  O=C(N)NO

• Molecular Formula :

  CH4N2O2

• Molecular Weight :

  76.05

• References & Citations :

  [1]Kovacic P, et al. Hydroxyurea (therapeutics and mechanism) : metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76 (1) :24-31.|[2]Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33 (12) :1486-92.|[3]Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7.|[4]Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95 (9) :1599-603.|[5]M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60 (2) :506-14. |[6]Kovacic P, et al. Hydroxyurea (therapeutics and mechanism) : metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76 (1) :24-31.|[7]Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33 (12) :1486-92.|[8]Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7.|[9]Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95 (9) :1599-603.|[10]M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60 (2) :506-14.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  4°C, sealed storage, away from light and moisture

• Scientific Category :

  Reference Standards

• Clinical Information :

  Launched

• CAS Number :

  [127-07-1]